Cargando…

IgG Antibody Response to SARS-CoV-2 Infection and Viral RNA Persistence in Patients on Maintenance Hemodialysis

Detalles Bibliográficos
Autores principales:	De Vriese, An S., Reynders, Marijke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the National Kidney Foundation, Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273159/ https://www.ncbi.nlm.nih.gov/pubmed/32512038 http://dx.doi.org/10.1053/j.ajkd.2020.05.009

Ejemplares similares

In Reply to ‘Is SARS-CoV-2 Serology Relevant for Hemodialysis Patients With COVID-19?’
por: De Vriese, An S., et al.
Publicado: (2020)

IgG SARS-CoV-2 Antibodies Persist at Least for 10 Months in Patients on Hemodialysis
por: Dudreuilh, Caroline, et al.
Publicado: (2021)

Persistence of IgG response to SARS-CoV-2
por: Duysburgh, Els, et al.
Publicado: (2021)

Long-Term Persistence of Anti-SARS-COV-2 IgG Antibodies
por: Yousefi, Zahra, et al.
Publicado: (2022)

Longevity and Clinical Effectiveness of the Humoral and Cellular Responses to SARS-CoV-2 Vaccination in Hemodialysis Patients
por: De Vriese, An S., et al.
Publicado: (2022)

SARS-CoV-2 IgG and IgA antibody response is gender dependent; and IgG antibodies rapidly decline early on
por: Korte, Wolfgang, et al.
Publicado: (2021)

Comparison of four commercial SARS-CoV-2 IgG immuno-assays in RT-PCR negative patients with suspect CT findings
por: Van Praet, Jens T., et al.
Publicado: (2020)

Kinetics of Anti–SARS-CoV-2 IgG Antibodies in Hemodialysis Patients Six Months after Infection
por: Sakhi, Hamza, et al.
Publicado: (2021)

Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure
por: Demonbreun, Alexis R., et al.
Publicado: (2021)

Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure
por: Demonbreun, Alexis R., et al.
Publicado: (2021)

Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines
por: Alharbi, Naif Khalaf, et al.
Publicado: (2022)

Nasopharyngeal Bacterial Microbiota Composition and SARS-CoV-2 IgG Antibody Maintenance in Asymptomatic/Paucisymptomatic Subjects
por: Ferrari, Luca, et al.
Publicado: (2022)

418. Comparison of the Abbott SARS-CoV-2 IgG and DiaSorin LIASON SARS-CoV-2 S1/S2 IgG Antibody Assays
por: Schaack, Grace A, et al.
Publicado: (2020)

Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies
por: Takahashi, Maika, et al.
Publicado: (2022)

Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG
por: Sapkal, Gajanan, et al.
Publicado: (2020)

SARS-COV-2 IgG and IgM Antibodies in Cancer Patients
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Clinical performance of different SARS‐CoV‐2 IgG antibody tests
por: Kohmer, Niko, et al.
Publicado: (2020)

SARS-CoV-2 IgG antibody responses in New York City
por: Reifer, Josh, et al.
Publicado: (2020)

Detection of SARS-CoV-2 IgG antibodies in dried blood spots
por: Turgeon, Coleman T., et al.
Publicado: (2021)

Anti-SARS-CoV-2 spike IgG antibodies prevalence: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2023)

Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection
por: Clark, Natasha M., et al.
Publicado: (2022)

Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil
por: Borges, Lysandro Pinto, et al.
Publicado: (2020)

Impact of heat-inactivation on the detection of SARS-CoV-2 IgM and IgG antibody by ELISA
por: Hu, Xiumei, et al.
Publicado: (2020)

Detection of IgM and IgG antibodies against SARS-CoV-2 in patients with autoimmune diseases
por: Teng, Jialin, et al.
Publicado: (2020)

Impact of MERS-CoV and SARS-CoV-2 Viral Infection on Immunoglobulin-IgG Cross-Reactivity
por: AlKhalifah, Joud Mohammed, et al.
Publicado: (2023)

Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection
por: Wan, Jinkai, et al.
Publicado: (2020)

Non-infectious status indicated by detectable IgG antibody to SARS-CoV-2
por: Denning, David W., et al.
Publicado: (2020)

Kinetics and performance of the Abbott architect SARS-CoV-2 IgG antibody assay
por: Hamilton, Fergus, et al.
Publicado: (2020)

Prevalence of IgG antibodies to SARS-CoV-2 among emergency department employees
por: Madsen, Troy, et al.
Publicado: (2020)

Evaluation of four laboratory-based SARS-CoV-2 IgG antibody immunoassays
por: Tanis, Jorg, et al.
Publicado: (2021)

Highly active engineered IgG3 antibodies against SARS-CoV-2
por: Kallolimath, Somanath, et al.
Publicado: (2021)

Not all SARS-CoV-2 IgG and neutralizing antibody assays are created equal
por: Lippi, Giuseppe, et al.
Publicado: (2022)

SARS-CoV2 IgG antibody: Seroprevalence among health care workers
por: Prakash, Om, et al.
Publicado: (2021)

Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors
por: Uyoga, Sophie, et al.
Publicado: (2021)

Prevalence of SARS-CoV-2 IgG antibodies among dental teams in Germany
por: Mksoud, Maria, et al.
Publicado: (2022)

Hexamerization of Anti-SARS CoV IgG1 Antibodies Improves Neutralization Capacity
por: Pande, Kalyan, et al.
Publicado: (2022)

Long-term trajectories of SARS-CoV-2 neutralizing antibodies and predictive value of first dose vaccination-induced IgG-antibodies in hemodialysis patients
por: Tillmann, F. P., et al.
Publicado: (2021)

Persistence of SARS-CoV-2 IgG Antibody Response among South African Adults: A Prospective Cohort Study
por: Adeniyi, Oladele Vincent, et al.
Publicado: (2023)

Clinical performance of a semi-quantitative assay for SARS-CoV2 IgG and SARS-CoV2 IgM antibodies
por: Jung, Joanna, et al.
Publicado: (2020)

Outliers Matter—Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies
por: Hocher, Berthold, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o4fqo461dvb62vkqumnb5assun